Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 1
1992 1
1993 1
1994 1
1995 1
1997 1
1999 3
2000 1
2001 3
2002 3
2003 5
2004 2
2005 1
2011 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics of alendronate.
Porras AG, Holland SD, Gertz BJ. Porras AG, et al. Clin Pharmacokinet. 1999 May;36(5):315-28. doi: 10.2165/00003088-199936050-00002. Clin Pharmacokinet. 1999. PMID: 10384857 Review.
Pharmacokinetics of intravenous alendronate.
Cocquyt V, Kline WF, Gertz BJ, Van Belle SJ, Holland SD, DeSmet M, Quan H, Vyas KP, Zhang KE, De Grève J, Porras AG. Cocquyt V, et al. Among authors: porras ag. J Clin Pharmacol. 1999 Apr;39(4):385-93. doi: 10.1177/00912709922007958. J Clin Pharmacol. 1999. PMID: 10197297 Clinical Trial.
Clinical pharmacology of alendronate sodium.
Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Gertz BJ, et al. Among authors: porras ag. Osteoporos Int. 1993;3 Suppl 3:S13-6. doi: 10.1007/BF01623002. Osteoporos Int. 1993. PMID: 8298197
Studies of the oral bioavailability of alendronate.
Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Gertz BJ, et al. Among authors: porras ag. Clin Pharmacol Ther. 1995 Sep;58(3):288-98. doi: 10.1016/0009-9236(95)90245-7. Clin Pharmacol Ther. 1995. PMID: 7554702 Clinical Trial.
Pharmacokinetics of etoricoxib in patients with renal impairment.
Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG, Geer LA, Wong PH, Cho M, Cote J, Marbury TC, Moncrief JW, Alcorn H Jr, Swan S, Sack MR, Robson RA, Petty KJ, Schwartz JI, Gottesdiener KM. Agrawal NG, et al. Among authors: porras ag. J Clin Pharmacol. 2004 Jan;44(1):48-58. doi: 10.1177/0091270003260338. J Clin Pharmacol. 2004. PMID: 14681341
Pharmacokinetics of etoricoxib in patients with hepatic impairment.
Agrawal NG, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC, Lasseter KC, Alam I, Petty KJ, Gottesdiener KM. Agrawal NG, et al. Among authors: porras ag. J Clin Pharmacol. 2003 Oct;43(10):1136-48. doi: 10.1177/0091270003257219. J Clin Pharmacol. 2003. PMID: 14517196 Clinical Trial.
The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ. Schwartz JI, et al. Among authors: porras ag. Clin Pharmacol Ther. 2000 Dec;68(6):626-36. doi: 10.1067/mcp.2000.112244. Clin Pharmacol Ther. 2000. PMID: 11180023 Clinical Trial.
28 results